Placeholder Banner

Biotech Analyst Optimism: Price Targets Post-IPO

September 9, 2014
In a recent blog post, Bruce Booth of Life Sci VC, writes about the relationship between a forecasted price target of a biotech stock and its current share price. If biotech stocks hit their current targets, it could be a good year, Booth writes:

“I’ll close with a thought experiment as an optimist: if, in line with historic data, 45% of the current IPO class hits their price targets at some point over the next 12-months, which implies a doubling of many recent biotech IPO’s stock prices, that would certainly be quite the year ahead for the biotech market. There are, of course, other possible futures, but that one is particularly intriguing.”

Read the full post on Life Sci VC